A team of researchers led by the University of California San Diego and Stanford University has developed a noninvasive method to monitor the ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

The U.S. Department of Defense has awarded up to $11.9 million to Oregon State University to invent new drug delivery technologies for protecting members of the military from a range of health threats ...

Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities ...

Intra-Cellular Therapies stock leapt more than 30% Monday morning, after Johnson & Johnson agreed to buy the ...

Ademi LLP is investigating Intra-Cellular Therapies (Nasdaq: ITCI) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson.

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

Intra-Cellular Therapies’ performance in the stock market has been impressive, especially considering the broader market environment. The company’s stock is up +52.51% year-to-date (YTD), a remarkable ...

J&J said it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into ...

Johnson & Johnson (NYSE: JNJ) is reportedly considering a bid for biopharmaceutical company Intracellular Therapies (NASDAQ: ...

Cravath, Swaine & Moore guided Johnson & Johnson in its $14.6 billion plan to purchase Intra-Cellular Therapies Inc., a ...

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...